title: Perceived Risk of Severe Respiratory Syncytial Virus Disease and Immunoprophylaxis Use Among US Pediatric Specialists.
abstract: This study was conducted to assess the perception of US pediatric specialists of respiratory syncytial virus (RSV) disease risk and determine their clinical practices regarding immunoprophylaxis for high-risk children. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Data were collected using structured questions requiring quantitative responses. Most neonatologists and pediatricians (>82.7%) reported a high clinical need for RSV immunoprophylaxis in preterm infants <32 weeks' gestational age. Pediatric pulmonologists and pediatric cardiologists suggested that health conditions indicative of chronic lung disease of prematurity and hemodynamically significant congenital heart disease, respectively, confer eligibility for RSV immunoprophylaxis. Agreement with the changes in the 2014 American Academy of Pediatrics guidance for RSV immunoprophylaxis was mixed among respondents from the 4 specialties. Survey findings may provide a basis to improve education about risk for severe RSV disease and evaluate changes in physician use of RSV immunoprophylaxis based on the 2014 guidance.
authors.affiliation: New York Medical College, Valhalla, NY, USA.
authors.forename: Deborah M
authors.initials: DM
authors.lastname: Friedman
authors.affiliation: Upstate Medical University, Syracuse, NY, USA.
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Domachowske
authors.affiliation: Children's Hospital, Los Angeles, CA, USA.
authors.forename: Pierre C
authors.initials: PC
authors.lastname: Wong
authors.affiliation: University of Kansas Hospital, Kansas City, KS, USA.
authors.forename: Prabhu S
authors.initials: PS
authors.lastname: Parimi
authors.affiliation: Arnold Palmer Hospital, Orlando, FL, USA.
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Garcia
authors.affiliation: Maimonides Medical Center, New York, NY, USA.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Marcus
authors.affiliation: AstraZeneca, Gaithersburg, MD, USA.
authors.forename: William V
authors.initials: WV
authors.lastname: La Via
authors.affiliation: ICON, Vancouver, BC, Canada.
authors.forename: Iqra A
authors.initials: IA
authors.lastname: Syed
authors.affiliation: ICON, Vancouver, BC, Canada.
authors.forename: Shelagh M
authors.initials: SM
authors.lastname: Szabo
authors.affiliation: AstraZeneca, Gaithersburg, MD, USA.
authors.forename: Kimmie K
authors.initials: KK
authors.lastname: McLaurin
authors.affiliation: AstraZeneca, Gaithersburg, MD, USA kumarve@medimmune.com.
authors.forename: Veena R
authors.initials: VR
authors.lastname: Kumar
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007114:Immunization; D008297:Male; D010372:Pediatrics / Q000706:statistics & numerical data*; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012306:Risk; D013038:Specialization; D011795:Surveys and Questionnaires; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal
keywords: RSV; cardiologist; neonatologist; palivizumab; pediatrician; pulmonologist